Clinical trial NCT04799392: NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons
Official title: NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: COVID-19
SARS-CoV-2
Coronavirus
Lead sponsor: NOWDiagnostics, Inc.
Sponsor class: INDUSTRY
First posted: 2021-03-16
Enrollment: 50
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device. The NOWDx COVID-19 Test is an in vitro lateral flow immunoassay intended for qualitative detection of total antibodies to SARS-CoV-2 in human fingerstick whole blood at the Point of Care (POC); i.e. in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation; and at home.

Detailed description: This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device. The NOWDx COVID-19 Test is an in vitro lateral flow immunoassay intended for qualitative detection of total antibodies to SARS-CoV-2 in human fingerstick whole blood at the Point of Care (POC); i.e. in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation; and at home.

The NOWDx COVID-19 Test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Testing of human fingerstick whole blood is intended to be conducted in a home-like setting of a facility authorized to perform CLIA waived tests.

Eligibility criteria: Inclusion Criteria:

Innate Infection Cohort\>

* PCR positives: persons who were symptomatic for COVID-19 and have tested positive for COVID-19 with an EUA or FDA cleared PCR test; 7+ days post positive PCR test
* PCR negatives: persons who have never had COVID-19 and who have tested negative for COVID-19 with an EUA or FDA cleared PCR test; within 0-6 days post negative PCR test
* persons 2+ years old

Vaccination Cohort\>

* persons 7- 60 days post second dose of EUA COVID-19 vaccine
* persons 18+ years old

Exclusion criteria:

Innate Infection Cohort\>

* PCR positives: persons with a COVID-19 positive test result \>45 days old
* PCR negatives: persons with any prior COVID-19 positive result
* persons who have received COVID-19 vaccine
* persons \<2 years old

Vaccination Cohort\>

* persons symptomatic or previously infected with COVID-19 prior to vaccination
* persons \<18 years old

Primary outcomes:
measure: Percentage of clinical agreement between NOWDx COVID-19 Test and emergency use authorized or FDA cleared comparator
timeFrame: through study completion; an average of 2 months
measure: Positivity rate of NOWDx COVID-19 Tests in vaccinated persons
timeFrame: through study completion; an average of 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Fayetteville
country: United States
facility: Medical Arts Pharmacy
state: Arkansas
city: Anoka
country: United States
facility: Goodrich Pharmacy
state: Minnesota
city: Nixa
country: United States
facility: Alps Specialty Pharmacy
state: Missouri
city: Springfield
country: United States
facility: Alps Pharmacy
state: Missouri
city: Richmond
country: United States
facility: Bremo Pharmacy
state: Virginia
Study officials:
affiliation: NOW Diagnostics, Inc.
name: Beth Cobb
role: PRINCIPAL_INVESTIGATOR
References: